Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Tailored prophylaxis in severe hemophilia A: Real-world experience with efanesoctocog alfa

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAmna GameilRDRawan DawoudSMShehab Mohamed

Discussion

Loading...

Member takes

Overview

Case reports show improved quality of life and adherence with efanesoctocog alfa prophylaxis in severe hemophilia A.

Key Points

  • The central aim is to evaluate the real-world effectiveness of efanesoctocog alfa in managing severe hemophilia A patients.
  • Descriptive case reports of two patients with severe hemophilia A managed with efanesoctocog alfa.
  • Assessment of pharmacokinetic profiles and quality of life measures pre-and post-treatment transitions.
  • Comparison of annualized bleeding rates before and after starting efanesoctocog alfa.
  • Both patients achieved an annualized bleeding rate of zero after switching to efanesoctocog alfa.
  • Improvements in quality of life were reported, with better adherence to treatment regimens.
  • Notable reductions in treatment burden and enhanced joint health were observed.

Cite This Study

Gameil et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbbfhttps://doi.org/10.1182/blood-2025-6626
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comprehensive Assessment of the Transition to Efanesoctocog Alfa Prophylaxis in a Paediatric Haemophilia A Cohort2026
  2. 2Clinical experience with efanesoctocog alfa in patients with uncover needs on emicizumab2025
  3. 3Quality of life and functional improvements with efanesoctocog alfa in patients with moderate-to-severe Hemophilia A: A real-world survey2025
  4. 4Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis2026
  5. 5Unmet needs despite standard-of-care prophylaxis in Hemophilia A: improved outcomes after switching to Efanesoctocog Alfa2026